Loading
Healthcare
9 min read
Areas of Expertise :
Gastroenterology, Infectious Diseases, Anesthesiology, Public Health, Product Liability
Published Date:
Last Modified Date:
Jurisdiction:
Nevada State
Teva Parenteral Medicines, Baxter Healthcare, and McKesson faced consolidated Nevada actions arising from the Las Vegas endoscopy outbreak, where plaintiffs alleged that selling 50 mL single-patient-use propofol vials to high-turnover ambulatory surgical centers posed a foreseeable risk of multi-dosing misuse and exposure. (In the 2010 Chanin trial, the defendants were Teva, including its Sicor affiliates, and Baxter; McKesson became involved later in the consolidated litigation and in the 2021 writ proceedings.) The Nevada Supreme Court entertained a writ of mandamus to decide whether these state-law claims were preempted by federal drug regulations, holding that some, but not all, claims are preempted. The record shows that propofol vials were supplied to Dr. Dipak Desai’s endoscopy centers, and in the consolidated actions, roughly 800 letter recipients treated between 2004 and 2008 all tested negative. These patients pursued claims to recover the costs of testing and the emotional distress associated with awaiting results.
Earlier proceedings included a Clark County jury verdict on May 7, 2010, awarding $5.1 million in compensatory damages and $500 million in punitive damages (a total of $505.1 million). The district court later entered final judgment, in the amount of $522.4 million, reflecting the verdict plus interest and fees, which defendants appealed on January 12, 2011. Published coverage appeared in early March 2011. In 2021, the Nevada Supreme Court held that negligence claims may proceed in part, and that plaintiffs’ request for punitive damages also survives to the extent it derives from the negligence claim, while directing dismissal of other theories identified as preempted. Plaintiffs argued that smaller vials, such as 20 mL, could have been adequate for many procedures, and that selling 50 mL vials into high-turnover ambulatory settings created a foreseeable risk of misuse, particularly in gastroenterology endoscopy practice.
In the consolidated actions, roughly 800 patients treated at Las Vegas endoscopy centers between 2004 and 2008, received warning letters advising hepatitis testing after reports of multi-dosing misuse of 50 mL single-patient-use propofol vials. According to the Nevada Supreme Court record, all of these letter recipients obtained testing and received negative results. They pursued recovery for testing costs and the emotional distress of awaiting results, asserting claims of strict product liability, breach of implied warranty, negligence, violations of the Nevada Deceptive Trade Practices Act, and punitive damages. Their allegations centered on the foreseeable misuse of 50 mL vials in high-throughput ambulatory settings, contrasted with the availability of smaller vials (such as 20 mL), which plaintiffs argued were sufficient for many procedures.
News coverage tied Henry Chanin’s 2006 diagnosis to an earlier procedure at Desert Shadow Endoscopy Center, describing arguments later raised on appeal about unsafe clinic practices and vial sizes. This individual matter became the first outbreak-related trial, shaping how jurors and later courts evaluated foreseeability and product presentation based on the documented misuse of single-patient-use vials and syringes.
A Clark County jury initially awarded $5.1 million in compensatory damages, plus $356 million in punitive damages against Teva and $144 million in punitive damages against Baxter, for a total of approximately $505.1 million. The district court later entered final judgment at $522.4 million, which defendants appealed in January 2011. The trial report highlights claims that the reuse of propofol vials labeled for single-patient-use contributed to infection risk at the endoscopy center. (McKesson was not a defendant in this trial, though it later appeared in the consolidated litigation and the 2021 writ proceedings.) This verdict became a touchstone for subsequent filings and defense appeals.
Published coverage early in March 2011, reported that Teva, Baxter, and Sicor argued the jury should have been presented with more evidence about the clinic’s unsafe practices and that the companies had appealed the $522.4 million judgment. The report also noted the involvement of prominent appellate counsel and suggested that additional outbreak-related cases could be influenced by the outcome. At that time, the verdict remained on appeal, and no acceptance or payment of the award had been reported.
Court-ordered talks produced settlements in 41 hepatitis C lawsuits, including resolution of the Chanin matter (approximately $505.1 million jury verdict, with final judgment entered at $522.4 million). Around the same time, public reporting confirmed that Teva settled approximately 120 lawsuits for $285 million, though individual settlement terms were confidential.
In Teva Parenteral Medicines, Inc.; Baxter; and McKesson v. Eighth Judicial District Court (No. 81024), the Nevada Supreme Court filed its opinion granting in part and denying in part a writ of mandamus. The Court held that negligence claims may proceed in part, and punitive damages requests tethered to those surviving negligence claims may also proceed, while all other theories are preempted by federal regulation. This ruling applied to the consolidated cases involving approximately 800 patients who received notification letters but tested negative. The Court’s opinion did not revisit or alter the earlier Chanin settlement, and it definitively resolved the preemption issue for the consolidated cases, though it did not determine final damages.
Court:
Supreme Court of Nevada
Case Name:
Teva Parenteral Medicines, Inc. v. Eighth Judicial District Court of the State of Nevada
Hepatitis
Infection Control
General Anesthesia
Pharmaceutical Product Liability
Drug Regulation
Healthcare Products
Safety Warnings
Damages Calculations
Teva Parenteral Medicines, Baxter Healthcare, and McKesson faced consolidated Nevada actions arising from the Las Vegas endoscopy outbreak, where plaintiffs alleged that selling 50 mL single-patient-use propofol vials to high-turnover ambulatory surgical centers posed a foreseeable risk of multi-dosing misuse and exposure. (In the 2010 Chanin trial, the defendants were Teva, including its Sicor affiliates, and Baxter; McKesson became involved later in the consolidated litigation and in the 2021 writ proceedings.) The Nevada Supreme Court entertained a writ of mandamus to decide whether these state-law claims were preempted by federal drug regulations, holding that some, but not all, claims are preempted. The record shows that propofol vials were supplied to Dr. Dipak Desai’s endoscopy centers, and in the consolidated actions, roughly 800 letter recipients treated between 2004 and 2008 all tested negative. These patients pursued claims to recover the costs of testing and the emotional distress associated with awaiting results.
Earlier proceedings included a Clark County jury verdict on May 7, 2010, awarding $5.1 million in compensatory damages and $500 million in punitive damages (a total of $505.1 million). The district court later entered final judgment, in the amount of $522.4 million, reflecting the verdict plus interest and fees, which defendants appealed on January 12, 2011. Published coverage appeared in early March 2011. In 2021, the Nevada Supreme Court held that negligence claims may proceed in part, and that plaintiffs’ request for punitive damages also survives to the extent it derives from the negligence claim, while directing dismissal of other theories identified as preempted. Plaintiffs argued that smaller vials, such as 20 mL, could have been adequate for many procedures, and that selling 50 mL vials into high-turnover ambulatory settings created a foreseeable risk of misuse, particularly in gastroenterology endoscopy practice.
In the consolidated actions, roughly 800 patients treated at Las Vegas endoscopy centers between 2004 and 2008, received warning letters advising hepatitis testing after reports of multi-dosing misuse of 50 mL single-patient-use propofol vials. According to the Nevada Supreme Court record, all of these letter recipients obtained testing and received negative results. They pursued recovery for testing costs and the emotional distress of awaiting results, asserting claims of strict product liability, breach of implied warranty, negligence, violations of the Nevada Deceptive Trade Practices Act, and punitive damages. Their allegations centered on the foreseeable misuse of 50 mL vials in high-throughput ambulatory settings, contrasted with the availability of smaller vials (such as 20 mL), which plaintiffs argued were sufficient for many procedures.
News coverage tied Henry Chanin’s 2006 diagnosis to an earlier procedure at Desert Shadow Endoscopy Center, describing arguments later raised on appeal about unsafe clinic practices and vial sizes. This individual matter became the first outbreak-related trial, shaping how jurors and later courts evaluated foreseeability and product presentation based on the documented misuse of single-patient-use vials and syringes.
A Clark County jury initially awarded $5.1 million in compensatory damages, plus $356 million in punitive damages against Teva and $144 million in punitive damages against Baxter, for a total of approximately $505.1 million. The district court later entered final judgment at $522.4 million, which defendants appealed in January 2011. The trial report highlights claims that the reuse of propofol vials labeled for single-patient-use contributed to infection risk at the endoscopy center. (McKesson was not a defendant in this trial, though it later appeared in the consolidated litigation and the 2021 writ proceedings.) This verdict became a touchstone for subsequent filings and defense appeals.
Published coverage early in March 2011, reported that Teva, Baxter, and Sicor argued the jury should have been presented with more evidence about the clinic’s unsafe practices and that the companies had appealed the $522.4 million judgment. The report also noted the involvement of prominent appellate counsel and suggested that additional outbreak-related cases could be influenced by the outcome. At that time, the verdict remained on appeal, and no acceptance or payment of the award had been reported.
Court-ordered talks produced settlements in 41 hepatitis C lawsuits, including resolution of the Chanin matter (approximately $505.1 million jury verdict, with final judgment entered at $522.4 million). Around the same time, public reporting confirmed that Teva settled approximately 120 lawsuits for $285 million, though individual settlement terms were confidential.
In Teva Parenteral Medicines, Inc.; Baxter; and McKesson v. Eighth Judicial District Court (No. 81024), the Nevada Supreme Court filed its opinion granting in part and denying in part a writ of mandamus. The Court held that negligence claims may proceed in part, and punitive damages requests tethered to those surviving negligence claims may also proceed, while all other theories are preempted by federal regulation. This ruling applied to the consolidated cases involving approximately 800 patients who received notification letters but tested negative. The Court’s opinion did not revisit or alter the earlier Chanin settlement, and it definitively resolved the preemption issue for the consolidated cases, though it did not determine final damages.
Gastroenterology Expert Witness
Gastroenterology expert witnesses are often engaged in outbreak-related litigation to explain the medical standards of care in endoscopy centers, anesthesia practices, and the risks of multi-dosing misuse of medications like propofol. They provide insight into how gastrointestinal procedures typically use single-patient vials, why dosing sizes matter, and how foreseeable misuse in high-volume clinics could affect patient safety. Their testimony helps courts and juries understand how endoscopy settings differ from other clinical contexts in drug administration.
Infectious Diseases Expert Witness
Infectious diseases experts are commonly consulted in cases involving outbreaks to clarify modes of transmission, incubation periods, and testing outcomes. In this litigation, their role would typically focus on explaining hepatitis C transmission risks and the public health response that led to testing approximately 800 patients. Their expertise provides scientific grounding for claims involving exposure, fear of infection, and the medical consequences of unsafe injection practices.
Public Health Expert Witness
Public health experts are often called in to describe how government health agencies respond to outbreaks and what protocols exist for patient notification and testing. They help contextualize the issuance of warning letters, the scale of testing, and how health systems manage exposure events in ambulatory surgical settings. Their input is critical in cases where large patient populations undergo precautionary testing despite negative results.
Economic Damages Expert Witness
Economic damages experts are usually retained to calculate the financial impact of testing, treatment costs, and non-economic harm such as emotional distress tied to fear of infection. They assist the court in quantifying both direct expenses and the intangible toll patients endure during prolonged medical uncertainty. Their testimony often helps juries translate widespread exposure into measurable compensation frameworks.
Toxicology and Anesthesiology Expert Witnesses
Toxicology and anesthesiology experts are often brought in to explain the pharmacological effects of drugs like propofol, appropriate dosage levels, and the risks of vial misuse in outpatient settings. Their role is to clarify safe dosing practices and to discuss arguments raised that smaller vials (such as 20 mL) could be adequate for many procedures. They also provide context on why larger 50 mL vials might increase the likelihood of multi-dosing in fast-paced gastroenterology endoscopy centers. Their perspective helps bridge the science of drug safety with the legal question of product foreseeability.
Federal Preemption as a Central Defense Strategy
The defense emphasized that FDA approval of propofol in multiple vial sizes and labeling should preempt state-law claims, framing compliance with federal regulation as a shield. The Nevada Supreme Court clarified that while some claims are preempted, negligence and related punitive damages requests may still proceed. This ruling highlights the importance of distinguishing between federally regulated labeling and broader state tort duties.
Foreseeability and Product Presentation in Healthcare Settings
Plaintiffs focused on the foreseeability of unsafe practices when 50 mL vials were sold into high-turnover ambulatory centers, arguing that smaller vials (such as 20 mL) could have been adequate for many procedures. This strategy positioned liability on the drug’s packaging and distribution context rather than solely on clinical misuse. Attorneys can draw from this by carefully analyzing how product design or sizing may influence behavior in specialized medical settings.
The Role of Punitive Damages in Shaping Settlement Pressure
The Chanin jury verdict, awarding approximately $500 million in punitive damages, demonstrates the outsized role of punitive awards in mass tort negotiations. While appellate courts may later narrow claims, early trial outcomes can frame the litigation landscape. Legal teams should recognize how punitive damage exposure can incentivize both settlement discussions and appellate strategies.
Use of Consolidated Actions for Public Health–Related Claims
Approximately 800 patients pursued consolidated actions after receiving warning letters advising hepatitis testing, even though all tests were negative. This approach reflects how plaintiffs may still recover for testing costs and emotional distress absent confirmed infection. Attorneys should note the potential breadth of liability in public health–driven litigation tied to healthcare outbreaks.
Appellate Advocacy as a Critical Litigation Stage
The 2011 appeal was pursued by Teva, Baxter, and Sicor, demonstrating how large trial verdicts can remain unsettled for years as appellate courts refine questions of preemption, damages, and negligence. McKesson later appeared as a petitioner in the 2021 writ proceedings, where the Nevada Supreme Court clarified which claims survived and reshaped the scope of ongoing litigation. These developments underscore how strategic appellate framing is essential to protect corporate defendants while preserving viable claims for plaintiffs.
The Nevada propofol litigation illustrates the complex intersection of product liability law, federal preemption, and state negligence claims. From the initial outbreak concerns at Las Vegas endoscopy centers through the approximately $505.1 million Clark County jury verdict and the Nevada Supreme Court’s later clarification, the dispute highlights how courts balance public safety concerns with federal regulatory frameworks. The case also underscores the importance of appellate strategy when multimillion-dollar judgments are at stake.
For gastroenterology and endoscopy practice, the litigation reflects broader implications about drug packaging, foreseeability of misuse, and patient safety in high-volume outpatient settings. The Nevada Supreme Court’s 2021 ruling left negligence and related punitive damages claims intact while dismissing others under federal preemption, showing how legal outcomes can shape both healthcare practices and product liability exposure. Attorneys studying this matter can draw lessons about regulatory interplay, evidentiary framing, and litigation strategies in healthcare-related disputes.
What triggered the Nevada gastroenterology endoscopy litigation?
The lawsuits arose after unsafe multi-dosing misuse of single-patient-use 50 mL propofol vials, which were misused for multiple patients at Las Vegas endoscopy centers, raising concerns about infection exposure. In the consolidated actions, roughly 800 patients treated between 2004 and 2008 received warning letters, all later tested negative, and sought compensation for testing costs and the emotional distress of awaiting results.
Who were the main companies involved in the litigation?
The core defendants across the litigation were Teva Parenteral Medicines, Baxter Healthcare, and McKesson, who manufactured and distributed the propofol vials. Teva and Baxter were defendants in the 2010 Chanin trial, while McKesson became involved later in the consolidated litigation and 2021 writ proceedings. Plaintiffs argued that selling larger vials created a foreseeable risk of unsafe reuse in ambulatory surgical settings.
What was the outcome of the 2010 jury trial?
In 2010, a Clark County jury awarded Henry and Lorraine Chanin $5.1 million in compensatory damages and approximately $500 million in punitive damages, for a total verdict of $505.1 million. The district court later entered final judgment at $522.4 million. This outcome was widely reported as a landmark award in Nevada.
How did the Nevada Supreme Court rule in 2021?
The Nevada Supreme Court ruled that negligence and related punitive damages claims could move forward, while other claims were barred by federal preemption. This clarified which legal avenues remained open without deciding on final damages.
What role did gastroenterology practices play in the dispute?
The litigation centered on endoscopy centers that used propofol vials during gastroenterology procedures. Plaintiffs argued that larger vial sizes encouraged unsafe practices in high-turnover outpatient clinics where such procedures were routinely performed.
Gastroenterology Expert Witness
Gastroenterology expert witnesses are often engaged in outbreak-related litigation to explain the medical standards of care in endoscopy centers, anesthesia practices, and the risks of multi-dosing misuse of medications like propofol. They provide insight into how gastrointestinal procedures typically use single-patient vials, why dosing sizes matter, and how foreseeable misuse in high-volume clinics could affect patient safety. Their testimony helps courts and juries understand how endoscopy settings differ from other clinical contexts in drug administration.
Infectious Diseases Expert Witness
Infectious diseases experts are commonly consulted in cases involving outbreaks to clarify modes of transmission, incubation periods, and testing outcomes. In this litigation, their role would typically focus on explaining hepatitis C transmission risks and the public health response that led to testing approximately 800 patients. Their expertise provides scientific grounding for claims involving exposure, fear of infection, and the medical consequences of unsafe injection practices.
Public Health Expert Witness
Public health experts are often called in to describe how government health agencies respond to outbreaks and what protocols exist for patient notification and testing. They help contextualize the issuance of warning letters, the scale of testing, and how health systems manage exposure events in ambulatory surgical settings. Their input is critical in cases where large patient populations undergo precautionary testing despite negative results.
Economic Damages Expert Witness
Economic damages experts are usually retained to calculate the financial impact of testing, treatment costs, and non-economic harm such as emotional distress tied to fear of infection. They assist the court in quantifying both direct expenses and the intangible toll patients endure during prolonged medical uncertainty. Their testimony often helps juries translate widespread exposure into measurable compensation frameworks.
Toxicology and Anesthesiology Expert Witnesses
Toxicology and anesthesiology experts are often brought in to explain the pharmacological effects of drugs like propofol, appropriate dosage levels, and the risks of vial misuse in outpatient settings. Their role is to clarify safe dosing practices and to discuss arguments raised that smaller vials (such as 20 mL) could be adequate for many procedures. They also provide context on why larger 50 mL vials might increase the likelihood of multi-dosing in fast-paced gastroenterology endoscopy centers. Their perspective helps bridge the science of drug safety with the legal question of product foreseeability.
Federal Preemption as a Central Defense Strategy
The defense emphasized that FDA approval of propofol in multiple vial sizes and labeling should preempt state-law claims, framing compliance with federal regulation as a shield. The Nevada Supreme Court clarified that while some claims are preempted, negligence and related punitive damages requests may still proceed. This ruling highlights the importance of distinguishing between federally regulated labeling and broader state tort duties.
Foreseeability and Product Presentation in Healthcare Settings
Plaintiffs focused on the foreseeability of unsafe practices when 50 mL vials were sold into high-turnover ambulatory centers, arguing that smaller vials (such as 20 mL) could have been adequate for many procedures. This strategy positioned liability on the drug’s packaging and distribution context rather than solely on clinical misuse. Attorneys can draw from this by carefully analyzing how product design or sizing may influence behavior in specialized medical settings.
The Role of Punitive Damages in Shaping Settlement Pressure
The Chanin jury verdict, awarding approximately $500 million in punitive damages, demonstrates the outsized role of punitive awards in mass tort negotiations. While appellate courts may later narrow claims, early trial outcomes can frame the litigation landscape. Legal teams should recognize how punitive damage exposure can incentivize both settlement discussions and appellate strategies.
Use of Consolidated Actions for Public Health–Related Claims
Approximately 800 patients pursued consolidated actions after receiving warning letters advising hepatitis testing, even though all tests were negative. This approach reflects how plaintiffs may still recover for testing costs and emotional distress absent confirmed infection. Attorneys should note the potential breadth of liability in public health–driven litigation tied to healthcare outbreaks.
Appellate Advocacy as a Critical Litigation Stage
The 2011 appeal was pursued by Teva, Baxter, and Sicor, demonstrating how large trial verdicts can remain unsettled for years as appellate courts refine questions of preemption, damages, and negligence. McKesson later appeared as a petitioner in the 2021 writ proceedings, where the Nevada Supreme Court clarified which claims survived and reshaped the scope of ongoing litigation. These developments underscore how strategic appellate framing is essential to protect corporate defendants while preserving viable claims for plaintiffs.
The Nevada propofol litigation illustrates the complex intersection of product liability law, federal preemption, and state negligence claims. From the initial outbreak concerns at Las Vegas endoscopy centers through the approximately $505.1 million Clark County jury verdict and the Nevada Supreme Court’s later clarification, the dispute highlights how courts balance public safety concerns with federal regulatory frameworks. The case also underscores the importance of appellate strategy when multimillion-dollar judgments are at stake.
For gastroenterology and endoscopy practice, the litigation reflects broader implications about drug packaging, foreseeability of misuse, and patient safety in high-volume outpatient settings. The Nevada Supreme Court’s 2021 ruling left negligence and related punitive damages claims intact while dismissing others under federal preemption, showing how legal outcomes can shape both healthcare practices and product liability exposure. Attorneys studying this matter can draw lessons about regulatory interplay, evidentiary framing, and litigation strategies in healthcare-related disputes.
What triggered the Nevada gastroenterology endoscopy litigation?
The lawsuits arose after unsafe multi-dosing misuse of single-patient-use 50 mL propofol vials, which were misused for multiple patients at Las Vegas endoscopy centers, raising concerns about infection exposure. In the consolidated actions, roughly 800 patients treated between 2004 and 2008 received warning letters, all later tested negative, and sought compensation for testing costs and the emotional distress of awaiting results.
Who were the main companies involved in the litigation?
The core defendants across the litigation were Teva Parenteral Medicines, Baxter Healthcare, and McKesson, who manufactured and distributed the propofol vials. Teva and Baxter were defendants in the 2010 Chanin trial, while McKesson became involved later in the consolidated litigation and 2021 writ proceedings. Plaintiffs argued that selling larger vials created a foreseeable risk of unsafe reuse in ambulatory surgical settings.
What was the outcome of the 2010 jury trial?
In 2010, a Clark County jury awarded Henry and Lorraine Chanin $5.1 million in compensatory damages and approximately $500 million in punitive damages, for a total verdict of $505.1 million. The district court later entered final judgment at $522.4 million. This outcome was widely reported as a landmark award in Nevada.
How did the Nevada Supreme Court rule in 2021?
The Nevada Supreme Court ruled that negligence and related punitive damages claims could move forward, while other claims were barred by federal preemption. This clarified which legal avenues remained open without deciding on final damages.
What role did gastroenterology practices play in the dispute?
The litigation centered on endoscopy centers that used propofol vials during gastroenterology procedures. Plaintiffs argued that larger vial sizes encouraged unsafe practices in high-turnover outpatient clinics where such procedures were routinely performed.
Was the $505.1 million jury verdict (and $522.4 million judgment) ever finalized?
The 2010 jury returned a verdict of approximately $505.1 million ($5.1 million in compensatory damages and approximately $500 million in punitive damages). The district court later entered final judgment at $522.4 million, which was appealed in January 2011. While the Nevada Supreme Court later clarified the scope of claims in 2021, the monetary judgment was no longer pending by that time. In February 2012, court-ordered talks produced settlements in 41 outbreak-related lawsuits, including resolution of the Chanin case. The terms of those settlements were confidential, but contemporaneous reports confirmed the resolution.
Hepatitis
Infection Control
General Anesthesia
Pharmaceutical Product Liability
Drug Regulation
Healthcare Products
Safety Warnings
Damages Calculations
Medical Devices, +4
Healthcare
Healthcare, +4
Healthcare
Was the $505.1 million jury verdict (and $522.4 million judgment) ever finalized?
The 2010 jury returned a verdict of approximately $505.1 million ($5.1 million in compensatory damages and approximately $500 million in punitive damages). The district court later entered final judgment at $522.4 million, which was appealed in January 2011. While the Nevada Supreme Court later clarified the scope of claims in 2021, the monetary judgment was no longer pending by that time. In February 2012, court-ordered talks produced settlements in 41 outbreak-related lawsuits, including resolution of the Chanin case. The terms of those settlements were confidential, but contemporaneous reports confirmed the resolution.